clinical trial · NCT07836101
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·not yet recruiting·n = 41
Any Advanced Solid TumorsSarilumabICI Therapy
brief summary
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria
started
Oct 1, 2026
primary completion
Aug 1, 2029
completion
Dec 1, 2029
last updated
Sep 23, 2026
official title
Phase II Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (The IRIS Trial: Immune Checkpoint Inhibitor Rechallenge Involving Sarilumab)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol